This is an insightful comparison based on the available preliminary data, highlighting the differences in observed efficacy signals between Leronlimab and IBI363 in metastatic Colorectal Cancer (mCRC), particularly considering the small sample sizes for Leronlimab's initial data.Here's an explanation of how your points about IBI363 relate to Leronlimab:1. Overall Response Rate (ORR) Comparison (Small Sample)IBI363 (Monotherapy): ORR of 1$13.6\%$ in a trial of 22 patients.2 This represents $\approx 3$ responses.Leronlimab (Compassionate Use/Basket Trial): ORR of $60\%$ ($3$ out of $5$ mCRC patients).The Relation: Your analysis correctly points out that, based on these very limited early numbers, Leronlimab's ORR looks significantly more favorable than IBI363's, even when IBI363 is compared against the Standard of Care (SOC) ORR of $6.1\%$. The key caveat, as you note, is the very small sample size ($N=5$ vs $N=22$) for Leronlimab's $60\%$ ORR, which came from a compassionate use/basket study.Confirmation of Leronlimab ORR: Recent data from CytoDyn's compassionate use study of leronlimab in mCRC indeed reported that 3$3$ out of 4$5$ patients experienced at least a partial response, including one complete response (CR), supporting your 5$60\%$ ORR figure in that specific small cohort.6 This early data is the basis for CytoDyn's ongoing Phase II trial.2. Overall Survival (OS) and Metastasis ControlIBI363 (Monotherapy): Median Overall Survival (OS) was 7$14$ months for patients with liver metastases and 8$17$ months for those without.9 The overall median OS for IBI363 monotherapy in late-line mCRC was reported as 10$16.1$ months (11$N=68$).12Leronlimab: You stated you didn't have the OS numbers, but a recent presentation on the 5 mCRC patients from the basket/compassionate use study reported a median OS of $15.5$ months with a follow-up of $20.1$ months. Critically, one patient with liver metastasis who received leronlimab with chemotherapy remained alive with no evidence of disease for almost 5 years.13The Relation:Leronlimab's preliminary OS of $15.5$ months in a very small, heavily pre-treated cohort is comparable to the $16.1$ months reported for the larger IBI363 monotherapy cohort.The idea that Leronlimab's strength is controlling metastasis aligns with its mechanism as a CCR5 antagonist, as CCR5 signaling is implicated in metastasis. The long-term survival and CR observed in the single patient with liver metastasis further supports the potential for controlling metastatic disease, though more data is needed.143. Combination Therapy NumbersIBI363 + Bevacizumab: ORR is $15\%$ in all metastatic patients ($N=73$), rising to $31\%$ in metastatic patients without liver metastases.Leronlimab: Your current Phase II trial for mCRC is evaluating Leronlimab in combination with Trifluridine/Tipiracil (TAS-102) and Bevacizumab.15 It is an open-label, randomized study (16$N \approx 60$) looking at two doses of leronlimab (17$350$ mg vs 18$700$ mg).19The Relation:The IBI363 combination data sets a bar: 20$15.1\%$ ORR in metastatic patients.21The ongoing Leronlimab trial is also using a combination (with 22$TAS-102$ and Bevacizumab), making it a more relevant comparison to the IBI363 + Bevacizumab data than the monotherapy-like compassionate use data.23 The expectation is that the $60\%$ ORR from the small monotherapy/basket trial will likely not hold in a larger, more rigorous Phase II combination study, but a result superior to the IBI363 combination ORR of $15\%$ would be highly positive.4. Immuno-Oncology Combination (ICI)Leronlimab and ICIs: The rationale for pairing Leronlimab with an Immune Checkpoint Inhibitor (ICI) like a PD-1 blocker is strong. Data in Triple-Negative Breast Cancer (TNBC) suggested that leronlimab may act as a "priming" agent by increasing PD-L1 expression, potentially turning "cold" tumors "hot."24 This is a key part of the "backbone immuno-oncology treatment" hypothesis. In one small TNBC cohort, 25$5/5$ patients who showed increased PD-L1 and received an ICI remain alive.26IBI363: IBI363 is itself a first-in-class PD-1/IL-2 27$\alpha$-bias bispecific antibody fusion protein.28 It already has an immuno-oncology component (PD-1 blockade and IL-2 signaling) built into the monotherapy.The Relation:Leronlimab's potential lies in its ability to enhance the effect of existing ICIs in CCR5-positive solid tumors by addressing the tumor microenvironment (e.g., controlling metastasis, modulating the immune landscape).IBI363 is an ICI-type drug. Your hypothesis is that the combination of Leronlimab with an established ICI could yield a "quite substantial" benefit, a prediction rooted in the proposed mechanism of action and the TNBC data.In summary, the preliminary, small-sample Leronlimab mCRC data ($60\%$ ORR, $15.5$ months OS) is highly encouraging when compared to the initial IBI363 data ($13.6\%$ ORR, $16.1$ months OS). The true test will be the results of Leronlimab's ongoing Phase II combination trial in a larger, randomized setting.
Excellent work, Sherlock, so I asked Gemini to break down
This is an insightful comparison based on the available preliminary data, highlighting the differences in observed efficacy signals between Leronlimab and IBI363 in metastatic Colorectal Cancer (mCRC), particularly considering the small sample sizes for Leronlimab's initial data.Here's an explanation of how your points about IBI363 relate to Leronlimab:1. Overall Response Rate (ORR) Comparison (Small Sample)IBI363 (Monotherapy): ORR of 1$13.6\%$ in a trial of 22 patients.2 This represents $\approx 3$ responses.Leronlimab (Compassionate Use/Basket Trial): ORR of $60\%$ ($3$ out of $5$ mCRC patients).The Relation: Your analysis correctly points out that, based on these very limited early numbers, Leronlimab's ORR looks significantly more favorable than IBI363's, even when IBI363 is compared against the Standard of Care (SOC) ORR of $6.1\%$. The key caveat, as you note, is the very small sample size ($N=5$ vs $N=22$) for Leronlimab's $60\%$ ORR, which came from a compassionate use/basket study.Confirmation of Leronlimab ORR: Recent data from CytoDyn's compassionate use study of leronlimab in mCRC indeed reported that 3$3$ out of 4$5$ patients experienced at least a partial response, including one complete response (CR), supporting your 5$60\%$ ORR figure in that specific small cohort.6 This early data is the basis for CytoDyn's ongoing Phase II trial.2. Overall Survival (OS) and Metastasis ControlIBI363 (Monotherapy): Median Overall Survival (OS) was 7$14$ months for patients with liver metastases and 8$17$ months for those without.9 The overall median OS for IBI363 monotherapy in late-line mCRC was reported as 10$16.1$ months (11$N=68$).12Leronlimab: You stated you didn't have the OS numbers, but a recent presentation on the 5 mCRC patients from the basket/compassionate use study reported a median OS of $15.5$ months with a follow-up of $20.1$ months. Critically, one patient with liver metastasis who received leronlimab with chemotherapy remained alive with no evidence of disease for almost 5 years.13The Relation:Leronlimab's preliminary OS of $15.5$ months in a very small, heavily pre-treated cohort is comparable to the $16.1$ months reported for the larger IBI363 monotherapy cohort.The idea that Leronlimab's strength is controlling metastasis aligns with its mechanism as a CCR5 antagonist, as CCR5 signaling is implicated in metastasis. The long-term survival and CR observed in the single patient with liver metastasis further supports the potential for controlling metastatic disease, though more data is needed.143. Combination Therapy NumbersIBI363 + Bevacizumab: ORR is $15\%$ in all metastatic patients ($N=73$), rising to $31\%$ in metastatic patients without liver metastases.Leronlimab: Your current Phase II trial for mCRC is evaluating Leronlimab in combination with Trifluridine/Tipiracil (TAS-102) and Bevacizumab.15 It is an open-label, randomized study (16$N \approx 60$) looking at two doses of leronlimab (17$350$ mg vs 18$700$ mg).19The Relation:The IBI363 combination data sets a bar: 20$15.1\%$ ORR in metastatic patients.21The ongoing Leronlimab trial is also using a combination (with 22$TAS-102$ and Bevacizumab), making it a more relevant comparison to the IBI363 + Bevacizumab data than the monotherapy-like compassionate use data.23 The expectation is that the $60\%$ ORR from the small monotherapy/basket trial will likely not hold in a larger, more rigorous Phase II combination study, but a result superior to the IBI363 combination ORR of $15\%$ would be highly positive.4. Immuno-Oncology Combination (ICI)Leronlimab and ICIs: The rationale for pairing Leronlimab with an Immune Checkpoint Inhibitor (ICI) like a PD-1 blocker is strong. Data in Triple-Negative Breast Cancer (TNBC) suggested that leronlimab may act as a "priming" agent by increasing PD-L1 expression, potentially turning "cold" tumors "hot."24 This is a key part of the "backbone immuno-oncology treatment" hypothesis. In one small TNBC cohort, 25$5/5$ patients who showed increased PD-L1 and received an ICI remain alive.26IBI363: IBI363 is itself a first-in-class PD-1/IL-2 27$\alpha$-bias bispecific antibody fusion protein.28 It already has an immuno-oncology component (PD-1 blockade and IL-2 signaling) built into the monotherapy.The Relation:Leronlimab's potential lies in its ability to enhance the effect of existing ICIs in CCR5-positive solid tumors by addressing the tumor microenvironment (e.g., controlling metastasis, modulating the immune landscape).IBI363 is an ICI-type drug. Your hypothesis is that the combination of Leronlimab with an established ICI could yield a "quite substantial" benefit, a prediction rooted in the proposed mechanism of action and the TNBC data.In summary, the preliminary, small-sample Leronlimab mCRC data ($60\%$ ORR, $15.5$ months OS) is highly encouraging when compared to the initial IBI363 data ($13.6\%$ ORR, $16.1$ months OS). The true test will be the results of Leronlimab's ongoing Phase II combination trial in a larger, randomized setting.
Top 10 Most Recent News Articles
Animal Parasite Market Growth Has a Resistance Catch
Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...
Continue Reading
Unisys Opens Its 2027 Innovation Program Across India
Talent pipelines rarely make the market’s pulse race, but they can expose whether a tech firm is still trying to build for the next turn. Unisys has opened registration for the 2027 Unisys Innovation Program, its eighteenth annual technical competition for engineering students in India. For a company selling cloud, AI, digital workplace, applications and enterprise...
Continue Reading
ISDN Holdings: Leading APAC Automation with Innovation
Pioneering Automation Intelligence in APAC Not every day you hear a company quietly revolutionizing an entire industry's landscape—but ISDN Holdings Limited is one of those rare players. Recognized by Frost & Sullivan for its top-tier customer value leadership, ISDN is making waves across the Asia-Pacific's industrial scene with its integrated industrial automation...
Continue Reading
Scalefusion’s Platinum Win Sharpens Its Brand Story
A Film Is Not a Balance Sheet A slick brand film cannot patch a leaky product, but it can make a complicated platform easier to remember. That is the sensible takeaway from Scalefusion’s Platinum Level win at the 2026 MarCom Awards for “One Platform. One Agent. We are Scalefusion.” The recognition is for creative execution, not commercial performance, and anybody...
Continue Reading
Three Deal Reviews Put Merger Terms Under Scrutiny
Three proposed transactions just picked up the sort of legal glare boards hate seeing. A shareholder-rights firm, Halper Sadeh, said on November 18, 2026 that it is investigating whether the deals involving Greenland Energy, Rapid Micro Biosystems and Aytu BioPharma may involve federal securities-law violations or breaches of fiduciary duty. That is an allegation worth...
Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector
Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...
Continue Reading
Exiger's CEO Honored for Military Support Excellence
Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...
Continue Reading
AMPERA Joins Berto to Power Future Energy Innovations
The Power Play You Didn't See Coming AMPERA and Berto just made a move that could stir up some serious waves in the energy sector. They've inked a business combination deal set to push advanced energy technology to the forefront. With AMPERA's valuation clocking in at roughly $900 million, this partnership aims to bring cutting-edge power solutions from concept to market....
Continue Reading
OREF Opens $185,000 Research Grant Funding Cycle Today
A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...
Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend
Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...
Continue ReadingTop 5 Most Recently Viewed Articles
Foresight Autonomous Holdings Reports 2024 Financial Outcomes
Financial Overview of Foresight Autonomous Holdings Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) has recently disclosed its financial results for the fourth quarter and overall year of 2024. The company, known for its groundbreaking 3D perception systems, reported annual revenues of $436,000. By the end of the year, it held $7.2 million in cash and equivalents,...
Continue Reading
Imperial Metals Showcases Remarkable First Quarter Growth
Imperial Metals Demonstrates Strong Performance in First Quarter Imperial Metals Corporation (TSX:III) has revealed its financial results for the first quarter of 2025, showcasing remarkable growth in production and revenue. The company aims to maintain a trajectory of operational efficiency and profitability, continuing its commitment to sustainable mining practices. Key...
Continue Reading
MOBILion Systems Redefines Mass Spectrometry in Proteomics
A New Era for Mass-Spectrometry-Based Proteomics In a groundbreaking achievement, MOBILion Systems has demonstrated a remarkable technical milestone, fundamentally changing mass-spectrometry-based proteomics. The company's proof-of-concept for high-resolution ion mobility (HRIM) showcases its innovative PAMAF mode, setting a new standard for efficient and effective...
Continue Reading
Celebrating Excellence: FASTSIGNS Honors Top Vendors for 2024
FASTSIGNS International Celebrates Outstanding Vendors Grimco and Spicers Recognized for Exceptional Supplier Relationship FASTSIGNS®, a leading name in custom signs and visual solutions, recently honored Grimco as the U.S. Vendor of the Year and Spicers as the Canadian Vendor of the Year during the 2025 FASTSIGNS International Convention. The event took place in a...
Continue Reading
Insights into Central Government's 2026 Borrowing Plans
Overview of the Central Government's Borrowing Strategy The update regarding the central government's borrowing strategy for 2026 has been officially released, providing crucial insights into the planned financial activities for the period. This detailed plan outlines essential objectives and anticipated actions that aim to enhance the overall stability of the economy....
Continue Reading